Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Enzo Biochem ( (ENZ) ) has shared an update.
On January 8, 2025, Enzo Biochem, Inc. received a notice of non-compliance from the New York Stock Exchange, as its market capitalization and stockholder’s equity fell below $50 million, and its average stock price was under $1.00 for 30 consecutive trading days. The company has 18 months to address the capitalization and equity issues and six months to resolve the stock price deficiency, during which its stock will continue trading on the NYSE. Enzo Biochem plans to submit a corrective plan by February 21, 2025, and is considering various alternatives to regain compliance, ensuring its continued listing on the exchange while maintaining adherence to other NYSE standards.
More about Enzo Biochem
Enzo Biochem, Inc. is a life sciences company that has been in operation for over 45 years, primarily through its Life Sciences division, Enzo Life Sciences. The company focuses on labeling and detection technologies from DNA to whole cell analysis, offering a comprehensive portfolio of high-quality products such as antibodies, genomic probes, assays, biochemicals, and proteins. These proprietary products and technologies are central to translational research and drug development in areas like cell biology, genomics, and small molecule chemistry. Enzo Biochem monetizes its technology through global sales and licensing.
YTD Price Performance: -7.78%
Average Trading Volume: 151,899
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $35.53M
See more insights into ENZ stock on TipRanks’ Stock Analysis page.
